Commentary

Video

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

Author(s):

Eunice Wang, MD
Conference|ASH Annual Meeting and Exposition

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Eunice S. Wang, MD, chief, Department of Medicine - Leukemia, leader, Leukemia Clinical Disease Team, Roswell Park Comprehensive Cancer Center, discusses the efficacy of adding ziftomenib to intensive induction in the treatment of patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia. These findings from the phase 1a KOMET-007 study (NCT05735184) were shared in a presentation at the 2024 ASH Annual Meeting.

Related Videos
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Related Content
Christopher Graham, MD, of University of Minnesota Medical School
January 10th 2025

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.
January 4th 2025

The OncFive: Top Oncology Articles for the Week of 12/29

Melanoma | Maris– stock.adobe.com
January 4th 2025

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy